Morgan Stanley
INBX

Morgan Stanley’s Inhibrx, Inc. Common Stock INBX Stock Holding History

Morgan Stanley’s Portfolio INBX Stock Details INBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-549,469
Closed -$19.2M – 8106
2024
Q1 		$19.2M Sell
549,469
-44,369
-7% -$1.62M ﹤0.01% 2744
2023
Q4 		$22.6M Buy
593,838
+211,068
+55% +$4.52M ﹤0.01% 3226
2023
Q3 		$7.02M Sell
382,770
-1,885
-0.5% -$39.4K ﹤0.01% 3443
2023
Q2 		$9.99M Buy
384,655
+8,435
+2% +$197K ﹤0.01% 3163
2023
Q1 		$7.1M Buy
376,220
+119,202
+46% +$2.77M ﹤0.01% 3467
2022
Q4 		$6.33M Buy
257,018
+95,985
+60% +$2.82M ﹤0.01% 3532
2022
Q3 		$2.89M Buy
161,033
+20,682
+15% +$373K ﹤0.01% 4159
2022
Q2 		$1.59M Sell
140,351
-144,068
-51% -$2.12M ﹤0.01% 4701
2022
Q1 		$6.34M Buy
284,419
+228,052
+405% +$5.82M ﹤0.01% 3426
2021
Q4 		$2.46M Buy
56,367
+53,099
+1,625% +$2.12M ﹤0.01% 4410
2021
Q3 		$108K Sell
3,268
-23,066
-88% -$702K ﹤0.01% 6327
2021
Q2 		$724K Sell
26,334
-8,894
-25% -$185K ﹤0.01% 5279
2021
Q1 		$707K Buy
35,228
+29,061
+471% +$849K ﹤0.01% 4949
2020
Q4 		$203K Buy
+6,167
New +$164K ﹤0.01% 5585

Other funds holding INBX

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Morgan Stanley's INBX Position: Q2 2024 in Review

Morgan Stanley sold out of Inhibrx, Inc. Common Stock (INBX) in Q2 2024, closing a stake of 549,469 shares — an estimated $19.2M sold.

Morgan Stanley first reported a position in INBX in Q4 2020 and held it in 14 quarters. The position peaked at $22.6M in Q4 2023. 2 funds tracked by Wall St. Rank hold INBX as of Q2 2024.

  • Morgan Stanley reported no remaining Inhibrx, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • Morgan Stanley sold 549,469 Inhibrx, Inc. Common Stock shares in Q2 2024, an estimated $19.2M.
  • Morgan Stanley first reported a position in Inhibrx, Inc. Common Stock in Q4 2020 and held it in 14 quarters.
  • Morgan Stanley's Inhibrx, Inc. Common Stock position peaked at $22.6M in Q4 2023.
  • 2 funds tracked by Wall St. Rank held Inhibrx, Inc. Common Stock as of Q2 2024.

Based on Morgan Stanley's 13F filing for Q2 2024, filed 14 Aug 2024.